2020 - Fellow of the American Association for the Advancement of Science (AAAS)
2010 - Member of the National Academy of Medicine (NAM)
John H. Krystal mostly deals with Neuroscience, Internal medicine, Psychiatry, Schizophrenia and Psychosis. His work carried out in the field of Neuroscience brings together such families of science as NMDA receptor and Glutamatergic. His NMDA receptor research integrates issues from Ketamine and Agonist.
His Internal medicine study combines topics in areas such as Anxiety disorder, Endocrinology and Antidepressant. His Psychiatry study incorporates themes from Cohort study, Clinical psychology and Child abuse. As part of the same scientific family, John H. Krystal usually focuses on Schizophrenia, concentrating on Dopamine receptor D2 and intersecting with Amphetamine.
His primary scientific interests are in Psychiatry, Neuroscience, Internal medicine, Clinical psychology and Schizophrenia. His research investigates the connection between Psychiatry and topics such as Alcohol dependence that intersect with issues in Genetics and Genome-wide association study. His Neuroscience research is multidisciplinary, incorporating elements of NMDA receptor and Glutamate receptor.
He works mostly in the field of NMDA receptor, limiting it down to concerns involving Pharmacology and, occasionally, Ketamine. His Internal medicine research includes themes of Anesthesia, Endocrinology and Major depressive disorder. His Clinical psychology study frequently draws parallels with other fields, such as Depression.
John H. Krystal focuses on Neuroscience, Clinical psychology, Ketamine, Depression and Posttraumatic stress. His Neuroscience study combines topics from a wide range of disciplines, such as NMDA receptor and Schizophrenia. The Schizophrenia study combines topics in areas such as Bipolar disorder, Hippocampus and Glutamatergic.
John H. Krystal interconnects Cognition, Association, Psychological resilience, Injury prevention and Occupational safety and health in the investigation of issues within Clinical psychology. His Ketamine study improves the overall literature in Psychiatry. His study in Placebo is interdisciplinary in nature, drawing from both Randomized controlled trial and Brief Psychiatric Rating Scale.
His primary areas of study are Neuroscience, Clinical psychology, Ketamine, Functional connectivity and Depression. The various areas that he examines in his Neuroscience study include Fingerprint and Schizophrenia. The concepts of his Schizophrenia study are interwoven with issues in NMDA receptor, Psychosis, Dopamine receptor D2, Dopamine and Glutamatergic.
His Clinical psychology study also includes fields such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
John H. Krystal;Laurence P. Karper;John P. Seibyl;Glenna K. Freeman.
Archives of General Psychiatry (1994)
Antidepressant effects of ketamine in depressed patients
Robert M Berman;Angela Cappiello;Amit Anand;Amit Anand;Dan A Oren;Dan A Oren.
Biological Psychiatry (2000)
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
M Laruelle;A Abi-Dargham;C H van Dyck;R Gil.
Proceedings of the National Academy of Sciences of the United States of America (1996)
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.
Ralitza Gueorguieva;John H. Krystal.
Archives of General Psychiatry (2004)
Social supports and serotonin transporter gene moderate depression in maltreated children.
Joan Kaufman;Bao Zhu Yang;Bao Zhu Yang;Heather Douglas-Palumberi;Shadi Houshyar.
Proceedings of the National Academy of Sciences of the United States of America (2004)
The psychotomimetic effects of intravenous Delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
Deepak Cyril D'Souza;Edward Perry;Lisa MacDougall;Yola Ammerman.
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.
Gerard Sanacora;Ralitza Gueorguieva;C. Neill Epperson;Yu-Te Wu.
Archives of General Psychiatry (2004)
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
A Abi-Dargham;R Gil;J Krystal;R M Baldwin.
American Journal of Psychiatry (1998)
Elevated CSF Corticotropin-Releasing Factor Concentrations in Posttraumatic Stress Disorder
J Bremner;Julio Licinio;Adam Darnell;John Krystal.
American Journal of Psychiatry (1997)
Psychobiologic Mechanisms of Posttraumatic Stress Disorder
Dennis S. Charney;Ariel Y. Deutch;John H. Krystal;Steven M. Southwick.
Archives of General Psychiatry (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: